Related Experiment Videos
[Community-acquired pneumonia in children: etiology and treatment]
1Hôpital Saint-Vincent-de-Paul, 74, Av Denfert-Rochereau, 75014 Paris, France. dominique.gendrel@svp.ap-hop-paris.fr
Insights
Community-acquired pneumonia in children often needs immediate antibiotic treatment. Amoxicillin is recommended, with macrolides for Mycoplasma pneumoniae, despite diagnostic challenges.
Area of Science:
- Pediatric infectious diseases
- Microbiology
- Clinical pharmacology
Context:
- Community-acquired pneumonia (CAP) in children necessitates prompt empiric antibiotic therapy due to diverse etiological agents.
- Streptococcus pneumoniae is a common cause (15-30%), often lacking specific diagnostic markers like characteristic radiological findings.
- Mycoplasma pneumoniae is prevalent in older children and adolescents (40-60%), requiring macrolide treatment to prevent sequelae.
Purpose:
- To review the diagnostic challenges and empiric antibiotic treatment strategies for community-acquired pneumonia in children.
- To highlight the importance of considering Streptococcus pneumoniae and Mycoplasma pneumoniae in pediatric pneumonia management.
- To discuss the impact of diagnostic limitations and evolving epidemiology on treatment decisions.
Summary:
- Empiric antibiotic selection for pediatric CAP must address Streptococcus pneumoniae, including penicillin-resistant strains, with amoxicillin as the preferred agent.
- High procalcitonin levels are a key indicator, while other laboratory data are less reliable for bacterial pneumonia diagnosis.
- Macrolides are crucial for Mycoplasma pneumoniae infections, especially in cases of amoxicillin treatment failure or suspected atypical pneumonia.
Impact:
- Current diagnostic methods for pediatric pneumonia present significant challenges, impacting timely and accurate treatment.
- Empiric antibiotic guidelines must balance the need to cover common bacterial pathogens with the risks of resistance and over-treatment.
- Future research should focus on immunised children to understand the evolving landscape of pneumococcal serotypes and their clinical significance.
Abstract:
Due to their very different etiological agents, community-acquired pneumoniae in children frequently require empiric antibiotic therapy in emergency. Streptococcus pneumoniae represents between 15 to 30% of the etiologies and has unspecific diagnostic procedures; as a matter of fact radiological lobar consolidation is seen in less than half of cases, and laboratory data, except for high procalcitonin level, are poorly reliable. Pneumonia due to Mycoplasma pneumoniae is frequent after 2 years of age, reaching 40 to 60% of causes in ambulatory teenagers; it must be treated with macrolides as sequellae are possible. The exact number of viral pneumonia is difficult to establish because of the lack of reliable diagnostic methods. If bacterial superinfections are probably overestimated during acute phase, viral infections may lead to bacterial pneumonia 2 to 4 weeks after the initial episode. Empiric antibiotic treatment must take into account pneumococci and their penicillin-resistant strains. Amoxicillin is the antibiotic of choice, having a higher efficacy on resistant pneumococci than oral cephalosporins. In case of clinical failure of amoxicillin, mycoplasma infection must be considered and patient must receive macrolides. Future epidemiology will be affected by anti-pneumococcal immunisation but difficulties in diagnosis and empiric antibiotic treatment will probably remain. Studies in immunised children are needed to evaluate the importance of pneumococcal infections due to serotypes not included in the vaccine.